Puma Biotechnology (PBYI) Non-Current Assets (2011 - 2026)

Puma Biotechnology has reported Non-Current Assets for 16 years, with the latest figure at $50.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 20.78% year-over-year to $50.4 million; the trailing twelve-month figure through Mar 2026 stood at $221.7 million (down 14.91% YoY), and the FY2025 full-year result was $53.6 million, down 18.36% from the prior year.
• Non-Current Assets for Q1 2026 stood at $50.4 million, down from $53.6 million in the prior quarter.
• The five-year high for Non-Current Assets was $87.8 million in Q4 2022, with the low at $50.4 million in Q1 2026.
• Historically, Non-Current Assets has averaged $70.5 million across 5 years, with a median of $71.1 million in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Assets climbed 3.24% — and 2026, when it decreased 20.78%.
• Puma Biotechnology's Non-Current Assets stood at $87.8 million in 2022, then retreated by 15.31% to $74.3 million in 2023, then slipped by 11.66% to $65.7 million in 2024, then dropped by 18.36% to $53.6 million in 2025, then retreated by 5.92% to $50.4 million in 2026.
• The last three Non-Current Assets figures came in at $50.4 million (Q1 2026), $53.6 million (Q4 2025), and $59.3 million (Q3 2025), per Business Quant data.